Global Cardiac Amyloidosis Market Growth Accelerates: Strategic Forecast Predicts $8.03 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Cardiac Amyloidosis Industry Market Size Be by 2025?
The valuation of the cardiac amyloidosis marketplace has demonstrated robust expansion over the immediately preceding years, projected to ascend from $5.26 billion in 2024 to $5.73 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 8.9% throughout this period. This upward trajectory observed during the historical timeframe is fundamentally linked to several key factors, principally the increasing incidence of maladies associated with amyloidosis, the greater detection of genetic alterations, heightened public and professional knowledge, the escalation in instances of transthyretin amyloidosis, alongside the demographic shift towards an older populace.

What's the Long-Term Growth Forecast for the Cardiac Amyloidosis Market Size Through 2029?
Forecasting robust expansion, the market catering to cardiac amyloidosis is projected to reach a valuation of $8.03 billion by the year 2029, achieving a compound annual growth rate (CAGR) of 8.8% over the coming period, a surge fueled by heightened rates of detection, augmented governmental backing and supportive actions, a growing incidence of hereditary alterations, and dedicated patient aid schemes. Key movements shaping this market throughout the projection timeframe encompass the advent of innovative treatments like vulrisiran, intensified investigations into the realm of gene therapy, a concentrated movement towards personalized medical approaches, continuous enhancements in diagnostic instrumentation, and the creation of entirely new therapeutic agents.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

What Are the Key Growth Drivers Fueling the Cardiac Amyloidosis Market Expansion?
Anticipated expansion of the senior demographic is set to drive the forward trajectory of the cardiac amyloidosis market. This demographic encompasses elderly individuals, generally those at sixty-five years old or more, who often necessitate specific medical attention and assistance stemming from age-related physiological shifts. Factors such as extended lifespans, progress in medical science, and falling birth rates are contributing to this demographic's growth. The expansion of this older cohort directly correlates with a higher incidence of cardiac amyloidosis, given that advancing age constitutes a primary vulnerability for the deposition of amyloid proteins within the cardiac muscle. To illustrate this trend, data from the Population Reference Bureau, a non-profit entity situated in the US, indicated in January 2024 that the American populace aged sixty-five years and over is projected to escalate from fifty-eight million recorded in 2022 up to eighty-two million by the year 2050, representing a forty-seven percent surge. Consequently, the growing number of older adults is poised to fuel expansion within the cardiac amyloidosis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp

What Are the Key Trends Driving Cardiac Amyloidosis Market Growth?
Key players within the cardiac amyloidosis sector are directing their efforts toward advancements in technology, specifically the deployment of diagnostic instruments reliant solely on artificial intelligence software, aiming to bolster the prompt identification and better the results for individuals afflicted by this frequently overlooked condition. A diagnostic apparatus for cardiac amyloidosis that employs AI exclusively through software constitutes a means of identification utilizing artificial intelligence to examine echocardiographic visuals, thereby pinpointing disease indicators without necessitating supplementary physical hardware or large compilations of patient data. To illustrate this progress, in November of 2024, the United Kingdom-based firm Ultromics Ltd. obtained approval from the FDA for EchoGo Amyloidosis, a sophisticated clinical application driven by AI designed for the early uncovering of cardiac amyloidosis; notably, this instrument marks the inaugural device granted marketing permission under the FDA's Total Product Lifecycle Advisory Program (TAP). Through the application of artificial intelligence, EchoGo Amyloidosis is capable of scrutinizing echocardiograms to recognize the presence of the illness from merely one recording, thereby satisfying the critical requirement for diagnosis at an earlier stage, before the condition advances without being noticed.

How Is the Cardiac Amyloidosis Market Segmented?
The cardiac amyloidosismarket covered in this report is segmented -

1) By Product Type: Light Chain Amyloidosis; Transthyretin Amyloidosis
2) By Treatment: Chemotherapy; Surgery; Supportive Care; Stem Cell Transplant; Targeted Therapy
3) By End-User: Hospitals; Ambulatory Surgical Centres; Clinics

Subsegments:
1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis; Primary Light Chain Amyloidosis; Secondary Light Chain Amyloidosis
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm); Wild-type Transthyretin Amyloidosis (ATTRwt)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21128&type=smp

Which Companies Are Leading the Charge in Cardiac Amyloidosis Market Innovation?
Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy's Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., Eidos Therapeutics.

Which Regions Are Leading the Global Cardiac Amyloidosis Market in Revenue?
North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21128

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.